5d
Zacks Investment Research on MSNIonis Out-Licenses Rights for Rare Blood Cancer Drug to OnoIonis Pharmaceuticals IONS signed a license agreement with Japan-based Ono Pharmaceutical. Per the terms, Ono has acquired ...
William Blair lifted their Q1 2026 earnings estimates for shares of Ionis Pharmaceuticals in a research note issued on ...
Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have ...
Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge ...
Piper Sandler analyst Allison Bratzel maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report) today and set a price ...
Learn more about whether Ionis Pharmaceuticals, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...
Arizona State Retirement System raised its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 8.8% in the ...
In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), ...
6d
GlobalData on MSNAstraZeneca and Ionis win EU approval for ATTR polyneuropathyAstraZeneca and Ionis Pharmaceuticals’ polyneuropathy drug has won approval in the European Union (EU), where it will be ...
Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains ...
CARLSBAD, Calif. & OSAKA, Japan, March 11, 2025--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results